TMPRSS2 and infection: The inhibitor appears to specifically block SARS-CoV-2 entry by the endosomal pathway, as it was highly effective on VeroE6 cells that lack TMPRSS2 but failed to inhibit infection of Calu-3 cells that expresses TMPRSS2, which enables SARS-CoV-2 to fuse at the plasma membrane [35].